AstraZeneca COVID-19 vaccine shows 74% efficacy in large U.S. trial
CHICAGO, Sept 29 (Reuters) - AstraZeneca Plc's (AZN.L) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease, a figure that increased to 83.5% in people aged 65 and older, according to long-awaited results of the company's U.S. clinical trial published on Wednesday. Overall efficacy of 74%...